IMU
Click for more information
6.67% 5.6¢ imugene limited

Latest Facebook Post from Imugene (10/02/20 @1545)

  1. MrCamino
    93 Posts.
    lightbulb Created with Sketch. 65
    clock Created with Sketch.
    10/02/20
    16:04
    Post #: 42845111
    HOT OFF THE PRESS TODAY. Outstanding new preclinical research from Professor Yuman Fong with Dr Yanghee Woo etal at the City of Hope Cancer Center, describing the development of Imugene's licensed oncolytic virus CheckVacc, which is entering the clinic in 2020.

    Abstract

    Background

    Peritoneal carcinomatosis (PC) from pancreatic ductal adenocarcinoma (PDAC) is fatal. Our preclinical study presents an effective treatment against PDAC PC employing a novel oncolytic viral agent, CF33-hNIS-antiPDL1.

    Study Design

    CF33-hNIS-antiPDL1 is a genetically engineered chimeric orthopoxvirus, CF33, armed with the human Sodium Iodide Symporter (hNIS) and anti-PD-L1 antibody (anti-PD-L1). The in vitro cytotoxic ability of this virus against five PDAC cell lines was tested at various doses (multiplicity of infection (MOI) = 0.01, 0.1, 1, 10). Production and blockade function of virus-encoded anti-PD-L1 antibody were verified using immunoblot, immunoprecipitation, and PD-1/PD-L1 bioassay. In vivo mouse models of PC, with or without subcutaneous (SC) tumors created by injecting AsPC-1-ffluc cells into nude mice, were treated with PBS or a single dose (1x105 plaque-forming units) of either intraperitoneal (IP) or intravenous (IV) injections of CF33-hNIS-antiPDL1. Mice with PC tumors were treated on days 0, 2, or 14 following tumor implantation.

    Results

    CF33-hNIS-antiPDL1 killed PDAC cells in a dose-dependent manner achieving >90% cell killing by day 8. Cells infected with CF33-hNIS-antiPDL1 produced bioactive anti-PD-L1 antibody which blocked PD-1/PD-L1 interaction. In vivo, single dose of virus reduced tumor burden and prolonged survival of treated mice. It was observed that IP administration of CF33-hNIS-antiPDL1 was more effective than IV administration

    Conclusion

    CF33-hNIS-antiPDL1 virus is effective in infecting and killing human PDACs and producing functional anti-PD-L1 antibody. IP delivery of CF33-hNIS-antiPDL1 effectively reduces peritoneal tumor burden and improves survival after only one dose and is superior to IV delivery.

    https://www.journalacs.org/article/S1072-7515(20)30115-0/abstract
    IMU Price at posting: 3.2¢ Sentiment: Buy Disclosure: Held
    Likes Created with Sketch. 43  Upvote
    lightbulb Created with Sketch. 7  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

LKE Lake Resources implies news article on job cuts made up; non-core sales "not material" and no rule 15.7 breach
right-arrow Created with Sketch.
IMR Imricor raises $35M to pursue growth and expansion into Australia and NZ
right-arrow Created with Sketch.
I88 Major fault system and magnetic anomalies discovered at Talus Uranium Prospect
right-arrow Created with Sketch.
MCT Metalicity looking for offers on Admiral Bay zinc project
right-arrow Created with Sketch.
NEWS Warren Tredrea’s weekly sports business wrap: the latest on business in sport
right-arrow Created with Sketch.
1CG One Click Group surpasses $3M in revenue YTD with 40% growth
right-arrow Created with Sketch.
watchlist Created with Sketch. Add IMU (ASX) to my watchlist
(20min delay)
Last
5.6¢ 		Change
-0.004(6.67%) 		Mkt cap ! $440.9M
Open High Low Value Volume
5.9¢ 5.9¢ 5.5¢ $708.1K 12.36M

Buyers (Bids)

No. Vol. Price($)
4 271098 5.6¢
 

Sellers (Offers)

Price($) Vol. No.
5.7¢ 813925 11
View Market Depth
Last trade - 10.35am 24/07/2024 (20 minute delay) ?
IMU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.